Developer docs
API playgroundTry for free, no card

Search company profiles

Ruminant BioTech

Full company profile

uuid0002ryq

Namestring
Ruminant BioTech
Legal namestring
Ruminant Biotech
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ruminant BioTech is a New Zealand-based agri-tech company founded in 2021 that develops a slow-release oral bolus device designed to suppress enteric methane emissions from cattle. The core product is a single-application capsule administered to ruminants that resides in the animal's rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, over approximately 100 days. Clinical trials have demonstrated sustained methane reductions of over 70% (with some results exceeding 90%) for more than three months per application, targeting the methanogen microbes responsible for roughly 95% of rumen methane output.

The bolus is differentiated by its delivery mechanism: unlike feed additives that require consistent dosing with every meal, the bolus is designed for pasture-based grazing systems where individual feed-dosing is impractical. The active ingredient is rapidly metabolised in the rumen, is not absorbed by the cow, and leaves no detectable residue in meat or dairy. The company holds patented technology for the slow-release bolus delivery system.

Ruminant BioTech is pre-commercial and plans to launch in New Zealand and Australia in 2026 following regulatory review under New Zealand's ACVM Act. Revenue will be generated through direct hardware sales of the bolus to dairy, sheep, and beef farmers operating pasture-based systems, with longer-term ambitions to expand across Brazil, Europe, the UK, USA, and Canada, targeting treatment of 100 million cows by 2035. The company is funded through a mix of venture capital (Regeneration.VC, NZGIF, AgriZeroNZ) and government grants from New Zealand, Australian, and Canadian government sources.

Short descriptiontext

Ruminant BioTech is a New Zealand agri-tech company developing a slow-release bolus that delivers the methane inhibitor bromoform to cattle rumens, achieving over 70% methane reduction for 3+ months per application, targeting pasture-based dairy and beef farmers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAuckland, New Zealand
HQ citystring
Auckland
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
methane mitigation bolus, livestock emissions reduction, enteric methane inhibitor, slow-release veterinary device, ruminant biotechnology
Industry2 codes
PRIMARYAFADAAAL
Medicated & Functional Ruminant Feed (Ionophores, Buffers, Yeast/Probiotics, Mycotoxin Binders)
Agriculture & Food Production/Animal Feed Manufacturing/Ruminant Feed (Cattle, Sheep, Goats)
SECONDARYAFADAAAK
Rumen-Protected & Bypass Nutrients (Protected Fats, Methionine/Lysine)
Agriculture & Food Production/Animal Feed Manufacturing/Ruminant Feed (Cattle, Sheep, Goats)
NAICS code1 code
  • Animal Food Manufacturing3111
SIC code1 code
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Livestock methane mitigation (agri-tech animal health device)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Methane-Reducing Bolus Product
TypeHardware Sales
Description

Pre-commercial stage. The company is developing a slow-release methane-inhibiting bolus for cattle that will be sold to farmers for application to their livestock. The bolus provides a 'set and forget' methane reduction solution practical for grass-fed/pasture-based farming operations.

ruminantbiotech.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ruminant BioTech has developed a slow-release ruminal bolus that delivers the methane inhibitor bromoform (tribromomethane) directly to the rumen of cattle over approximately 90–100 days from a single oral application. The bolus has demonstrated sustained methane emissions reduction of over 70% (with earlier trials showing >90% knockdown) and is designed as a 'set and forget' solution tailored to pasture-based dairy, sheep, and beef farming systems. The product is currently pre-commercial and undergoing regulatory approval under New Zealand's ACVM Act ahead of a planned NZ and Australia launch in 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% methane knockdown demonstrated in trials; sustained methane knockdown for over 3 months
+3 more records
Product overview1 text field

Ruminant BioTech offers a single core product: the methane-inhibiting bolus. This is a sustained-release capsule designed to reside in the rumen of cattle, delivering a naturally occurring methane inhibitor (bromoform/tribromomethane) over approximately three months. The bolus is designed specifically for pasture-grazed cattle systems and represents the company's sole commercial offering, targeting the reduction of enteric methane emissions from livestock. The company is currently in the regulatory approval phase with plans for commercial launch in New Zealand and Australia in 2026.

Product and service1 record
1Methane-Inhibiting Bolus
CategoryLivestock methane mitigation (slow-release bolus / agri-tech animal health device)
Description

Patented slow-release bolus administered orally to cattle that resides in the rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, for approximately 90–100 days per single application. Demonstrated over 70% (and in earlier trials over 90%) methane knockdown sustained for 3+ months, designed as a 'set and forget' solution for dairy, sheep, and beef farmers operating pasture-based systems with no detectable residue in meat or dairy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or Integration
Description

R&D partner collaborating on research and development of the methane-inhibiting bolus technology for dairy cattle.

Strategic tierCoreTypeTechnology or Integration
Description

Academic R&D partner providing research expertise and collaboration for the methane mitigation technology development.

Strategic tierCoreTypeTechnology or Integration
Description

R&D partner specializing in agricultural research supporting the development and testing of the methane-reducing bolus.

Strategic tierSupportingTypeTechnology or Integration
Description

Medical research partner contributing expertise to the R&D programme.

Strategic tierSupportingTypeTechnology or Integration
Description

Research partner providing analytical and research capabilities for product development.

Strategic tierSupportingTypeTechnology or Integration
Description

Veterinary epidemiology partner supporting research and data analysis.

Strategic tierSupportingTypeTechnology or Integration
Description

Laboratory partner providing analytical testing services for the R&D programme.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major dairy co-operative and industry collaborator providing industry expertise and potential market access for the methane reduction solution.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Industry body representing sheep and beef farmers, collaborating on product development and market introduction.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Industry collaborator supporting the development and adoption of methane reduction solutions in grassland farming systems.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CH4 Global develops Asparagopsis seaweed-based feed supplements to reduce enteric methane from cattle. It competes directly with Ruminant BioTech in the methane-mitigation-for-livestock category, though using a feed-additive rather than bolus delivery mechanism, making it a clear direct peer addressing the same problem from a different angle.

TypeBroad incumbent
Description

Elanco commercializes Bovaer (3-NOP), a direct methane-inhibiting feed additive developed with DSM-firmenich and approved in multiple major dairy markets. As a large incumbent animal-health company with global distribution, it is the most established competitive threat to Ruminant BioTech's commercial ambitions.

TypeBroad incumbent
Description

dsm-firmenich co-developed the 3-NOP active ingredient behind Bovaer with Elanco and is a global leader in animal nutrition and health. It represents a deep-pocketed incumbent competing in the same methane-reduction category with a different delivery format.

TypeEmerging player
Description

ArkeaBio is developing a methane-reducing vaccine for cattle, representing an alternative mechanism (immunological) for enteric methane mitigation. As an early-stage company pursuing a different route to the same outcome, it is a relevant emerging peer with potential to disrupt the broader category.

TypeDirect peer
Description

Mootral produces a feed-additive product combining garlic and citrus extracts to reduce enteric methane in cattle. It is a direct peer competing for the same dairy and beef farmer customers, though delivering methane reduction through daily feed inclusion rather than a long-acting bolus.

TypeDirect peer
Description

Symbrosia is a US-based startup commercializing Asparagopsis seaweed-based feed supplements for livestock methane reduction. It competes in the same agricultural methane-mitigation category with a different delivery mechanism, making it a direct peer targeting overlapping customer segments.

TypeDirect peer
Description

Volta Greentech produces seaweed-based cattle feed supplements (Aimilox) targeting enteric methane reduction. As another seaweed-feed-additive competitor addressing the same problem, it is a direct peer in the methane-mitigation category for ruminants.

TypeBroad incumbent
Description

Zoetis is the largest global animal-health company and has publicly explored enteric-methane reduction opportunities. As a broad incumbent with established veterinary distribution and R&D infrastructure, it represents a potential acquirer or competitor with the resources to enter the methane-mitigation space at scale.

TypeBroad incumbent
Description

Alltech is a global animal nutrition company that has invested in methane-reduction research programs and feed-additive solutions. As an established broad incumbent in ruminant nutrition, it competes for the same farmer customer base and has the scale to influence market direction.

TypeBroad incumbent
Description

Cargill is a global agribusiness and animal nutrition major that has invested in methane-mitigation solutions and sustainability programs for livestock supply chains. Its scale, supply-chain reach, and processor relationships make it a broad incumbent peer that could either partner with or compete against Ruminant BioTech in major markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ruminant BioTech

Livestock methane mitigation (agri-tech animal health device)ruminantbiotech.com

Ruminant BioTech is a New Zealand agri-tech company developing a slow-release bolus that delivers the methane inhibitor bromoform to cattle rumens, achieving over 70% methane reduction for 3+ months per application, targeting pasture-based dairy and beef farmers globally.

What Ruminant BioTech does

Ruminant BioTech is a New Zealand-based agri-tech company founded in 2021 that develops a slow-release oral bolus device designed to suppress enteric methane emissions from cattle. The core product is a single-application capsule administered to ruminants that resides in the animal's rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, over approximately 100 days. Clinical trials have demonstrated sustained methane reductions of over 70% (with some results exceeding 90%) for more than three months per application, targeting the methanogen microbes responsible for roughly 95% of rumen methane output.

The bolus is differentiated by its delivery mechanism: unlike feed additives that require consistent dosing with every meal, the bolus is designed for pasture-based grazing systems where individual feed-dosing is impractical. The active ingredient is rapidly metabolised in the rumen, is not absorbed by the cow, and leaves no detectable residue in meat or dairy. The company holds patented technology for the slow-release bolus delivery system.

Ruminant BioTech is pre-commercial and plans to launch in New Zealand and Australia in 2026 following regulatory review under New Zealand's ACVM Act. Revenue will be generated through direct hardware sales of the bolus to dairy, sheep, and beef farmers operating pasture-based systems, with longer-term ambitions to expand across Brazil, Europe, the UK, USA, and Canada, targeting treatment of 100 million cows by 2035. The company is funded through a mix of venture capital (Regeneration.VC, NZGIF, AgriZeroNZ) and government grants from New Zealand, Australian, and Canadian government sources.

Ruminant BioTech firmographics

Firmographics
Name
Ruminant BioTech
Legal name
Ruminant Biotech
Website
https://ruminantbiotech.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Ruminant BioTech is a New Zealand agri-tech company developing a slow-release bolus that delivers the methane inhibitor bromoform to cattle rumens, achieving over 70% methane reduction for 3+ months per application, targeting pasture-based dairy and beef farmers globally.
Ownership category
akta.pro rank

Ruminant BioTech industry classification

Industry
Product category
Livestock methane mitigation (agri-tech animal health device)
NAICS
Animal Food Manufacturing (3111)
SIC
Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYAFADAAAL
Medicated & Functional Ruminant Feed (Ionophores, Buffers, Yeast/Probiotics, Mycotoxin Binders)
Agriculture & Food Production/Animal Feed Manufacturing/Ruminant Feed (Cattle, Sheep, Goats)
SECONDARYAFADAAAK
Rumen-Protected & Bypass Nutrients (Protected Fats, Methionine/Lysine)
Agriculture & Food Production/Animal Feed Manufacturing/Ruminant Feed (Cattle, Sheep, Goats)

Keywords

  • Methane mitigation bolus
  • Livestock emissions reduction
  • Enteric methane inhibitor
  • Slow-release veterinary device
  • Ruminant biotechnology

Where Ruminant BioTech is headquartered

Location

Headquarters

HQ city
Auckland
HQ country
New Zealand
HQ region
Oceania

Offices1 record

Markets served

Ruminant BioTech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Methane-Reducing Bolus Product: Pre-commercial stage. The company is developing a slow-release methane-inhibiting bolus for cattle that will be sold to farmers for application to their livestock. The bolus provides a 'set and forget' methane reduction solution practical for grass-fed/pasture-based farming operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Ruminant BioTech product offering

Product offering

Core offering

Ruminant BioTech has developed a slow-release ruminal bolus that delivers the methane inhibitor bromoform (tribromomethane) directly to the rumen of cattle over approximately 90–100 days from a single oral application. The bolus has demonstrated sustained methane emissions reduction of over 70% (with earlier trials showing >90% knockdown) and is designed as a 'set and forget' solution tailored to pasture-based dairy, sheep, and beef farming systems. The product is currently pre-commercial and undergoing regulatory approval under New Zealand's ACVM Act ahead of a planned NZ and Australia launch in 2026.

Product overview

Ruminant BioTech offers a single core product: the methane-inhibiting bolus. This is a sustained-release capsule designed to reside in the rumen of cattle, delivering a naturally occurring methane inhibitor (bromoform/tribromomethane) over approximately three months. The bolus is designed specifically for pasture-grazed cattle systems and represents the company's sole commercial offering, targeting the reduction of enteric methane emissions from livestock. The company is currently in the regulatory approval phase with plans for commercial launch in New Zealand and Australia in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Methane-Inhibiting Bolus Patented slow-release bolus administered orally to cattle that resides in the rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, for approximately 90–100 days per single application. Demonstrated over 70% (and in earlier trials over 90%) methane knockdown sustained for 3+ months, designed as a 'set and forget' solution for dairy, sheep, and beef farmers operating pasture-based systems with no detectable residue in meat or dairy.

Quantifiable outcome

  • Over 90% methane knockdown demonstrated in trials; sustained methane knockdown for over 3 months
  • +3 more outcomes

Companies that use Ruminant BioTech

Customer profile

Segments2 records

Ideal customer profiles2 records

Ruminant BioTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ruminant BioTech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • Dairy NZcoreTechnology or IntegrationR&D partner collaborating on research and development of the methane-inhibiting bolus technology for dairy cattle.
  • University of WaikatocoreTechnology or IntegrationAcademic R&D partner providing research expertise and collaboration for the methane mitigation technology development.
  • Ag ResearchcoreTechnology or IntegrationR&D partner specializing in agricultural research supporting the development and testing of the methane-reducing bolus.
  • ESP MedicalsupportingTechnology or IntegrationMedical research partner contributing expertise to the R&D programme.
  • CognoscosupportingTechnology or IntegrationResearch partner providing analytical and research capabilities for product development.
  • EpiVetssupportingTechnology or IntegrationVeterinary epidemiology partner supporting research and data analysis.
  • Analytica LaboratoriessupportingTechnology or IntegrationLaboratory partner providing analytical testing services for the R&D programme.
  • FonterracoreStrategic or Co-development PartnerMajor dairy co-operative and industry collaborator providing industry expertise and potential market access for the methane reduction solution.
  • Beef+Lamb NZcoreStrategic or Co-development PartnerIndustry body representing sheep and beef farmers, collaborating on product development and market introduction.
  • GrasslandssupportingStrategic or Co-development PartnerIndustry collaborator supporting the development and adoption of methane reduction solutions in grassland farming systems.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Ruminant BioTech competitors and assessment

Company assessment

Direct peers

  • CH4 Global: CH4 Global develops Asparagopsis seaweed-based feed supplements to reduce enteric methane from cattle. It competes directly with Ruminant BioTech in the methane-mitigation-for-livestock category, though using a feed-additive rather than bolus delivery mechanism, making it a clear direct peer addressing the same problem from a different angle.
  • Mootral: Mootral produces a feed-additive product combining garlic and citrus extracts to reduce enteric methane in cattle. It is a direct peer competing for the same dairy and beef farmer customers, though delivering methane reduction through daily feed inclusion rather than a long-acting bolus.
  • Symbrosia: Symbrosia is a US-based startup commercializing Asparagopsis seaweed-based feed supplements for livestock methane reduction. It competes in the same agricultural methane-mitigation category with a different delivery mechanism, making it a direct peer targeting overlapping customer segments.
  • Volta Greentech: Volta Greentech produces seaweed-based cattle feed supplements (Aimilox) targeting enteric methane reduction. As another seaweed-feed-additive competitor addressing the same problem, it is a direct peer in the methane-mitigation category for ruminants.

Broad incumbents

  • Elanco Animal Health: Elanco commercializes Bovaer (3-NOP), a direct methane-inhibiting feed additive developed with DSM-firmenich and approved in multiple major dairy markets. As a large incumbent animal-health company with global distribution, it is the most established competitive threat to Ruminant BioTech's commercial ambitions.
  • dsm-firmenich: dsm-firmenich co-developed the 3-NOP active ingredient behind Bovaer with Elanco and is a global leader in animal nutrition and health. It represents a deep-pocketed incumbent competing in the same methane-reduction category with a different delivery format.
  • Zoetis: Zoetis is the largest global animal-health company and has publicly explored enteric-methane reduction opportunities. As a broad incumbent with established veterinary distribution and R&D infrastructure, it represents a potential acquirer or competitor with the resources to enter the methane-mitigation space at scale.
  • Alltech: Alltech is a global animal nutrition company that has invested in methane-reduction research programs and feed-additive solutions. As an established broad incumbent in ruminant nutrition, it competes for the same farmer customer base and has the scale to influence market direction.
  • Cargill: Cargill is a global agribusiness and animal nutrition major that has invested in methane-mitigation solutions and sustainability programs for livestock supply chains. Its scale, supply-chain reach, and processor relationships make it a broad incumbent peer that could either partner with or compete against Ruminant BioTech in major markets.

Emerging players

  • ArkeaBio: ArkeaBio is developing a methane-reducing vaccine for cattle, representing an alternative mechanism (immunological) for enteric methane mitigation. As an early-stage company pursuing a different route to the same outcome, it is a relevant emerging peer with potential to disrupt the broader category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ruminant BioTech social profiles

Digital presence

Ruminant BioTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ruminant BioTech leadership team

Management profile

Number of profiles

Profiles18 records

Ruminant BioTech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ruminant BioTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ruminant BioTech

What does Ruminant BioTech do?

Ruminant BioTech has developed a slow-release ruminal bolus that delivers the methane inhibitor bromoform (tribromomethane) directly to the rumen of cattle over approximately 90–100 days from a single oral application. The bolus has demonstrated sustained methane emissions reduction of over 70% (with earlier trials showing >90% knockdown) and is designed as a 'set and forget' solution tailored to pasture-based dairy, sheep, and beef farming systems. The product is currently pre-commercial and undergoing regulatory approval under New Zealand's ACVM Act ahead of a planned NZ and Australia launch in 2026.

Is Ruminant BioTech a public or private company?

Ruminant BioTech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ruminant BioTech founded?

Ruminant BioTech was founded in 2021. It employs 11 to 50 people.

Where is Ruminant BioTech based?

Ruminant BioTech is headquartered in Auckland, New Zealand, in the Oceania region.

How does Ruminant BioTech make money?

One revenue line is on record: methane-Reducing Bolus Product.

Who are Ruminant BioTech's main competitors?

Direct peers on record are CH4 Global, Mootral, Symbrosia and Volta Greentech. Broad incumbents are Elanco Animal Health, dsm-firmenich, Zoetis, Alltech and Cargill. ArkeaBio is listed as an emerging player.

Does Ruminant BioTech have an API?

No public API is recorded for Ruminant BioTech.

What industry is Ruminant BioTech in?

Ruminant BioTech's product category is Livestock methane mitigation (agri-tech animal health device). Its primary akta.pro industry code is AFADAAAL, Medicated & Functional Ruminant Feed (Ionophores, Buffers, Yeast/Probiotics, Mycotoxin Binders), with a secondary code of AFADAAAK, Rumen-Protected & Bypass Nutrients (Protected Fats, Methionine/Lysine). Its NAICS code is 3111 and its SIC code is 200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NDTV Profit70% Emission Cut? Inside New Zealand's Push For 'Climate-Friendly' CowsNew Zealand researchers are trialing multiple technologies including feed additives, slow-release capsules, vaccines, and selective breeding to reduce methane emissions from cattle by up to 70% without affecting milk and meat production. Auckland-based Ruminant BioTech is awaiting regulatory approval for a slow-release capsule designed to suppress methane-producing microbes in ruminants. The initiative is being positioned as a potential model for other livestock-producing countries, particularly India which has the world's largest livestock population and estimated methane emissions of 12.74 teragrams from its livestock sector in 2019.Business StandardNew Zealand is testing ways to make cows climate-friendly: What it meansNew Zealand is testing multiple technologies including feed additives, slow-release capsules, vaccines, and selective breeding to reduce methane emissions from cattle without affecting milk or meat production. Auckland-based Ruminant BioTech is awaiting regulatory approval for its methane-suppressing capsule, which research indicates could reduce emissions per animal by up to 70 per cent. Researchers view New Zealand as an important test case, as any successful technology could be adopted by other livestock-producing countries like India, which has the world's largest livestock population.EXPANSIONCómo Nueva Zelanda se convirtió en un laboratorio mundial para vacas respetuosas con el climaNew Zealand is positioning itself as a real-world testing ground for methane reduction technologies in livestock, with Ruminant BioTech awaiting regulatory approval for a stomach bolus that could cut emissions per animal by up to 70%. AgriZeroNZ, a public-private partnership backed by NZ$191 million from the government and ten industry players including Fonterra and a2 Milk Co, has invested in 18 companies developing inhibitors, vaccines, probiotics, and selective breeding programs. The government has also announced an additional NZ$51 million funding program over three years to accelerate adoption of these technologies among farmers.AgFunderNewsRuminant BioTech eyes Canada as launchpad for global expansion with $5.6m research programRuminant BioTech, a New Zealand-based startup, has launched a CAD$7.6 million ($5.6 million) three-year on-farm research program in Canada to validate its slow-release methane reduction bolus technology for pasture-raised beef cattle, with the company establishing its North American base in Calgary to oversee the project. The program is supported by a CAD$2.8 million grant from the government of Alberta and CAD$3.4 million in co-funding from two industry partners, alongside CAD$1.4 million from Ruminant BioTech's own funds. The company, which achieved a 75% methane reduction in animal trials with a single dose lasting over 100 days, aims to use Canada as a launchpad for global expansion into the US, Brazil, and EU markets, targeting 100 million cows treated by 2035.BetaKitAlberta invests $28 million in six projects to improve environmental outcomesThe Government of Alberta is investing $28 million from its TIER industrial carbon pricing fund into six environmental technology projects announced by Emissions Reduction Alberta (ERA). The funded projects span renewable natural gas, methane reduction, pipeline safety, and oil recovery technologies across companies including Central Farms RNG, CNERGREEN Corp., Ruminant Biotech, Total Containment Inc., Tourmaline Oil Corp., and the University of Calgary. ERA estimates these projects could reduce 72,000 tonnes of CO2 annually and generate $166.5 million in GDP for Alberta by 2027 if successful.SmartCompanyFour ANZ startups that raised $52.1 million this weekFour ANZ startups—Pay.com.au, Ruminant Biotech, Australis Scientific, and Paperly—collectively raised $52.1 million in new funding this week to support market expansion and product development. Pay.com.au secured the largest share at $25 million to enter the US market, while Ruminant Biotech and Australis Scientific raised funds for methane reduction technology and medical device trials respectively. Paperly raised $3 million to expand its educational administration platform into the UK and Asia.BusinessDeskRuminant Biotech closes $17 million series A raiseAgritech start-up Ruminant Biotech has closed a $17 million Series A investment round as it prepares to enter commercial production in 2026. The raise was co-led by New Zealand investment companies Rosrain Investments and Cultivate Ventures, with significant participation from global financial services platform Marex. The funding will support the company's transition from development to commercial operations next year.AgFunderNewsCan a slow-release bolus crack methane reduction for pasture raised cattle? Ruminant BioTech nets $9.5mNew Zealand-based Ruminant BioTech has secured a $17 million NZD ($9.5 million) Series A funding round to launch its methane reduction bolus for pasture-raised cattle by 2026. The bolus reportedly can reduce methane emissions by 75% for over three months, with plans to extend this to six months, as the company aims to treat 100 million cows globally by 2035. The funding will facilitate commercial production and regulatory approvals in New Zealand and other countries including Canada, Brazil, and the EU.NZ HeraldRuminant Biotech raises $17m at $132m valuation for its cow pill that will slash methane emissionsRuminant Biotech has raised $17 million in a Series A funding round to commercialize its methane-reducing cattle pill, with plans for an initial launch in New Zealand and Australia next year. The company intends to use the funds to scale manufacturing and develop a carbon credit market model supported by investor Marex, aiming to treat thousands of animals by year-end. This expansion occurs as both nations adjust their agricultural methane emission targets, creating a specific regulatory environment for the product's adoption.Capital BriefRuminant Biotech raises $15m to scale livestock emissions-reduction techRuminant Biotech has secured NZD17 million (approximately $14.8 million) in a Series A investment round co-led by Rosrain Investments and Cultivate Ventures, with participation from Marex and AgriZeroNZ, to launch what it claims is the first methane reduction solution for pasture-based cattle in Australia and New Zealand in 2026. The New Zealand-founded agritech company will also use the funds to advance regulatory approvals in priority markets including Canada, Brazil, and the European Union, while accelerating technology development for additional cattle market segments. Ruminant previously received over NZD11 million in grants to fund development and initiate regulatory approval processes.